1. Selective modification of fluciclovine ((18)F) transport in prostate carcinoma xenografts
- Author
-
J. S. Lee, Funmilayo Tade, Weiping Yu, G. Lu, E. J. Teoh, S. Oka, Baowei Fei, Carlos S. Moreno, David M. Schuster, C. Ormenisan Gherasim, Mark M. Goodman, Dattatraya Patil, H. Okudaira, Adeboye O. Osunkoya, Birdal Bilir, Oladunni Akin-Akintayo, and W. G. Wiles
- Subjects
Male ,Luminescence ,medicine.medical_treatment ,Clinical Biochemistry ,Carboxylic Acids ,Mice, Nude ,Biochemistry ,Article ,030218 nuclear medicine & medical imaging ,Isobutyric acid ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,Mice ,0302 clinical medicine ,In vivo ,Cell Line, Tumor ,Positron Emission Tomography Computed Tomography ,medicine ,Animals ,Humans ,Saline ,Chemistry ,Organic Chemistry ,Prostate ,Prostatic Neoplasms ,Biological Transport ,Prostate carcinoma ,medicine.disease ,In vitro ,Partial inhibition ,030220 oncology & carcinogenesis ,Cancer research ,Heterografts ,Cyclobutanes - Abstract
We investigated if previously demonstrated inhibition of fluciclovine ((18)F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Partial inhibition of fluciclovine uptake by BCH and MeAIB can be demonstrated in vivo similar to previous in vitro modeling.
- Published
- 2018